Skip to main content
IDWeek 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Live Streamed
Live Streamed
On Demand
On Demand
Back

Raphael J. Landovitz, MD, MSc

Professor of Medicine; Director
UCLA Center for Clinical AIDS Research & Education
Los Angeles, CA, United States

Raphael J. Landovitz, MD, MSc, is Professor of Medicine and interim Chief of the Division of Infectious Diseases at the David Geffen School of Medicine; He also serves as Director of the UCLA Center for Clinical AIDS Research & Education. He graduated from Princeton University in 1992 and received his MD from Harvard Medical School in 1996, and completed residency in Internal Medicine at Brigham and Women’s Hospital and Infectious Diseases fellowship at the Brigham and Womens/Massachusetts General Hospital program. He served as Medical Chief Resident at Brigham and Women’s Hospital in 2001-02. Since 2013, he served as the leader of the Clinical Research Site (CRS) at the UCLA CARE Center and Co-PI of the UCLA AIDS Prevention and Treatment Clinical Trials Unit in 2020. He is also the Co-Director of the National Institute of Mental Health-funded Center for HIV Identification Prevention and Treatment Services (CHIPTS). His research is focused on the optimization of the use of antiretroviral medication for both HIV treatment and HIV prevention.

Dr. Landovitz has been part of the leadership of the NIAID-funded AIDS Clinical Trial Groups (ACTG), HIV Prevention Trial Network (HPTN), and the Adolescent Trial Network (ATN). He serves on the Executive Committee of the HIV Prevention Trials Network and was awarded the HIVMA HIV Research Award in 2017. He leads several biomedical and behavioral prevention intervention studies and projects using Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) strategies for men who have sex with men and cis- and transgender women. He was the principal investigator of two multisite PrEP demonstration projects in Los Angeles County and he led the NIH/DAIDS-funded Phase 2 and Phase 3 registrational clinical trials evaluating long-acting injectable cabotegravir for PrEP, which contributed to recent US FDA and multiple other regulatory approvals. He currently is evaluating implementation of long-acting injectable PrEP, as well as continuing to study other investigational long-acting/extended release products for HIV prevention.

Disclosure(s): Gilead Sciences: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); RedQueen Therapeutics: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing); Viiv Healthcare: Advisor/Consultant (Ongoing), Scientific Advisory Board member (Ongoing)

Presentation(s):